The Use of TrkA-PathHunter Assay in High-Throughput Screening to Identify Compounds That Affect Nerve Growth Factor Signaling

The TrkA-PathHunter cell-based assay was used in high-throughput screening (HTS) to identify compounds that inhibit nerve growth factor (NGF)/TrkA signaling. The assay was conducted in a 384-well format, and typical Z′ values during HTS ranged from 0.3 to 0.8. The reproducibility of IC50 values was good, and the use of cryopreserved cells was well tolerated, as judged by assay parameters such as Z′ and S/B and by comparison of IC50 values obtained with cells in culture. During hit deconvolution, TrkA-kinase inhibitors were identified with ATP-competitive as well as non–ATP-competitive mechanisms of action. Furthermore, other mechanisms of action such as NGF and TrkA antagonists were also identified. Because of the different molecular mechanisms identified, it is possible that subsequent optimization work to increase affinity and selectivity might lead to compounds that could have a better chance to evoke clinical efficacy without the adverse effects observed for nonselective TrkA inhibitors.

[1]  Y. Shu,et al.  Structural and functional insights into lipid‐bound nerve growth factors , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  M. Grimes,et al.  NGF Causes TrkA to Specifically Attract Microtubules to Lipid Rafts , 2012, PloS one.

[3]  Ove Almkvist,et al.  Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimer’s Disease , 2012, Dementia and Geriatric Cognitive Disorders.

[4]  S. Allen,et al.  Targeting Nerve Growth Factor in Pain , 2012, BioDrugs.

[5]  D. Hunter,et al.  Emerging drugs for osteoarthritis , 2011, Expert opinion on emerging drugs.

[6]  D. Ginty,et al.  Recruitment of Actin Modifiers to TrkA Endosomes Governs Retrograde NGF Signaling and Survival , 2011, Cell.

[7]  Y. Indo.  Nerve growth factor, pain, itch and inflammation: lessons from congenital insensitivity to pain with anhidrosis , 2010, Expert review of neurotherapeutics.

[8]  M. Bothwell,et al.  Neurotrophin receptors: Old friends with new partners , 2010, Developmental neurobiology.

[9]  J. Eibl,et al.  Multipotent Neurotrophin Antagonist Targets Brain-Derived Neurotrophic Factor and Nerve Growth Factor , 2010, Journal of Pharmacology and Experimental Therapeutics.

[10]  S. Capsoni,et al.  Development of a non invasive NGF-based therapy for Alzheimer's disease. , 2009, Current Alzheimer research.

[11]  M. Lamb,et al.  Trk kinase inhibitors as new treatments for cancer and pain , 2009, Expert opinion on therapeutic patents.

[12]  J. Pons,et al.  Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti‐NGF monoclonal antibody, using a repertoire of biosensors , 2008, Protein science : a publication of the Protein Society.

[13]  David A. Scott,et al.  Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases. , 2008, Journal of medicinal chemistry.

[14]  M. Hancock,et al.  Cellular Assays for High-Throughput Screening for Modulators of Trk Receptor Tyrosine Kinases , 2008, Current chemical genomics.

[15]  Ping Chen,et al.  Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkA. , 2008, Bioorganic & medicinal chemistry letters.

[16]  D. Stein,et al.  Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death , 2007, Proceedings of the National Academy of Sciences.

[17]  E. Birman,et al.  Neurotrophic rationale in glaucoma: A TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo , 2007, Developmental neurobiology.

[18]  A. Granholm,et al.  Nerve growth factor in treatment and pathogenesis of Alzheimer's disease , 2006, Progress in Neurobiology.

[19]  L. Reichardt,et al.  Neurotrophin-regulated signalling pathways , 2006, Philosophical Transactions of the Royal Society B: Biological Sciences.

[20]  Matthew D. Wessel,et al.  Discovery of novel isothiazole inhibitors of the TrkA kinase: structure-activity relationship, computer modeling, optimization, and identification of highly potent antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[21]  T. Ohgami,et al.  Orally active neurotrophin-enhancing agent protects against dysfunctions of the peripheral nerves in hyperglycemic animals. , 2006, Diabetes.

[22]  A. Konnerth,et al.  Neurotrophin-mediated rapid signaling in the central nervous system: mechanisms and functions. , 2005, Physiology.

[23]  K. Burgess,et al.  Long-Lasting Rescue of Age-Associated Deficits in Cognition and the CNS Cholinergic Phenotype by a Partial Agonist Peptidomimetic Ligand of TrkA , 2004, The Journal of Neuroscience.

[24]  H. Senn,et al.  Automation of biomolecular NMR screening. , 2003, Current topics in medicinal chemistry.

[25]  E Schwarz,et al.  The pro-sequence facilitates folding of human nerve growth factor from Escherichia coli inclusion bodies. , 2001, European journal of biochemistry.

[26]  T. Angeles,et al.  Quantitative, high-throughput cell-based assays for inhibitors of trkA receptor. , 2000, Analytical biochemistry.

[27]  R. Riopelle,et al.  Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. , 1999, The Journal of pharmacology and experimental therapeutics.

[28]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[29]  S. Halegoua,et al.  Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Lotz,et al.  The nerve growth factor/tumor necrosis factor receptor family , 1996, Journal of leukocyte biology.

[31]  J. Marks,et al.  Kynurenic Acid Derivatives Inhibit the Binding of Nerve Growth Factor ( NGF) to the Low‐Affinity p75 NGF Receptor. , 1996 .

[32]  B. Gibbs,et al.  Small Peptide Mimics of Nerve Growth Factor Bind TrkA Receptors and Affect Biological Responses (*) , 1995, The Journal of Biological Chemistry.

[33]  A. J. Shaka,et al.  Water Suppression That Works. Excitation Sculpting Using Arbitrary Wave-Forms and Pulsed-Field Gradients , 1995 .

[34]  P. Brehm,et al.  Neuronal growth factor regulation of two different sodium channel types through distinct signal transduction pathways , 1993, The Journal of cell biology.